HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

arginylproline

first & second amino acid in substance P sequence; RN given refers to (L)-isomer
Also Known As:
Arg-Pro; arginylproline diacetate, (L)-isomer
Networked: 198 relevant articles (3 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Miao, Yubin: 7 articles (11/2014 - 04/2009)
2. Yang, Jianquan: 6 articles (11/2014 - 04/2009)
3. Islam, Mohammad Safiqul: 4 articles (06/2020 - 10/2014)
4. Wei, Qingyi: 4 articles (08/2012 - 09/2002)
5. Mostaid, Md Shaki: 3 articles (01/2021 - 10/2014)
6. Mahanta, Jagadish: 3 articles (05/2017 - 03/2011)
7. Ahmed, Maizbha Uddin: 3 articles (01/2017 - 10/2014)
8. Hasnat, Abul: 3 articles (01/2017 - 10/2014)
9. Flook, Adam M: 3 articles (11/2014 - 09/2013)
10. Guo, Haixun: 3 articles (06/2012 - 04/2009)

Related Diseases

1. Myopia
2. Inflammation (Inflammations)
3. Papillomavirus Infections
4. Neoplasms (Cancer)
5. Melanoma (Melanoma, Malignant)
10/10/2013 - "The purpose of this study was to examine the effects of the -Arg-Pro-(RP) and -Gly-Gly-Nle- (GGNle) moieties on the melanoma targeting and clearance properties of 99mTc-peptides. "
09/03/2013 - "RTD-Lys-(Arg(11))CCMSH {c[Asp-Arg-Thr-Asp-DTyr]-Lys-Cys-Cys-Glu-His-DPhe-Arg-Trp-Cys-Arg-Pro-Val-NH2} and RVD-Lys-(Arg(11))CCMSH peptides were synthesized, and their melanocortin-1 (MC1) receptor binding affinities were determined in B16/F1 melanoma cells. "
05/01/2013 - "Our meta-analysis showed that TP53 Arg72Pro polymorphism was not associated with non-melanoma skin cancer susceptibility in overall population.(for Arg/Arg vs. Pro/Pro: OR 0.98, 95% CI 0.80-1.19; for Arg/Pro vs. Pro/Pro: OR 0.99, 95% CI 0.84-1.17; for the recessive model Arg/Arg vs. Arg/Pro + Pro/Pro: OR 1.10, 95% CI 0.89-1.35; for the dominant model Arg/Arg + Arg/Pro vs. Pro/Pro: OR 1.00, 95% CI 0.85-1.18). "
11/13/2014 - "RSD-β-Ala-(Arg(11))CCMSH (1) {c[Arg-Ser-Asp-dTyr-Asp]-β-Ala-Cys-Cys-Glu-His-dPhe-Arg-Trp-Cys-Arg-Pro-Val-NH2}, RTD-β-Ala-(Arg(11))CCMSH (2), RVD-β-Ala-(Arg(11))CCMSH (3), RAD-β-Ala-(Arg(11))CCMSH (4), NAD-β-Ala-(Arg(11))CCMSH (5), and EAD-β-Ala-(Arg(11))CCMSH (6) peptides were synthesized and evaluated for their melanocortin 1 (MC1) receptor binding affinities in B16/F1 melanoma cells. "
11/14/2013 - "RSD-Lys-(Arg(11))CCMSH {c[Arg-Ser-Asp-DTyr-Asp]-Lys-Cys-Cys-Glu-His-dPhe-Arg-Trp-Cys-Arg-Pro-Val-NH2}, RNleD-Lys-(Arg(11))CCMSH, RPheD-Lys-(Arg(11))CCMSH, and RdPheD-Lys-(Arg(11))CCMSH peptides were synthesized and evaluated for their melanocortin-1 (MC1) receptor binding affinities in B16/F1 melanoma cells. "

Related Drugs and Biologics

1. arginylarginine (Arg-Arg)
2. Peptides (Polypeptides)
3. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4. valylvaline (Val-Val)
5. Hypoxanthine
6. leucyl-lysyl-tyrosine
7. lysylglutamic acid
8. histidylproline
9. azelaic acid (Azelex)
10. Codon (Codons)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Lasers (Laser)
3. Colectomy
4. Intranasal Administration